Release date: 2018-03-26
Recently, Caris Life Sciences, which focuses on precision medicine, announced that its ADAPT Biotargeting system can significantly predict the therapeutic effect of Herceptin (trastuzumab) on breast cancer patients compared to the standard HER2 test. The results of this study were published in Nature Communications and are expected to be used for precise stratification of breast cancer patients.
In this study, the researchers first collected pre-treatment tumor samples, and then divided the patients into two groups based on the actual treatment effect, one group could benefit from treatment, and the other group had little effect. Subsequently, the researchers used 10^13 unique single-stranded DNA probes to detect unique binding patterns in the two groups of tumor samples, and obtained two sets of probe libraries, a group that favored binding to benefit from treatment. Tumor samples, the other group tend to combine tumor samples with ineffective treatment.
The researchers then tested them in 61 independent patient samples. Studies have shown that the new methods developed by them have significantly improved overall specificity and sensitivity compared to commonly used methods.
â–²The sensitivity and specificity of the new method is superior to conventional methods (Source: Caris Life Sciences)
“Although the current companion diagnosis has had a positive impact on cancer care, we have not done enough. For example, vemurafenib has a remission rate of only 50% in patients with V600E mutant melanoma, and olaparib is a BRCA mutation-positive breast cancer patient. The response rate is only 35%,†said David D. Halbert, CEO of Caris Life Sciences. “This study shows that our own technology is expected to lead to better diagnostic testing.â€
“In HER2-positive breast cancer patients, only 38%-50% of patients benefit from the treatment of trastuzumab, which reflects the need for better diagnostic techniques,†said Dr. David Spetzler, Chief Scientific Officer of Caris Life Sciences. "This proof-of-concept experiment shows that the ADAPT Biotargeting system can detect subtle genetic network differences and better predict the response to trastuzumab than the traditional HER2 test."
We expect this technology to lead to more precise patient stratification, regardless of whether it can benefit from the treatment of trastuzumab, patients can use the right drugs as soon as possible.
Reference materials:
[1] Caris Life Sciences Announces Published Results Showing that its ADAPT Biotargeting System Effectively Stratified Breast Cancer Patients Based on Their Benefit from Trastuzumab Treatment (Herceptin)
[2] Caris Life Sciences Official Website
Source: WuXi PharmaTech
Dingmin Pharmaceutical supply Apixaban API and Apixaban Intermediates with high purity and best price. The main products CAS No are as follows: 503612-47-3, 545445-44-1,473927-63-8, 503614-91-3. Sample can be sent if you request. Most of the products are stock available. Also can be custom.
Welcome to do business with us. Please email to us directly.
Cas 503612-47-3 ,Apixaban Intermediates,4-Methoxyphenyl
Shijiazhuang Dingmin pharmaceutical Sciences Co.,Ltd , https://www.dingminpharma.com